Results 1 to 10 of about 790 (70)

Distinct roles of interleukin-17 and T helper 17 cells among autoimmune diseases

Journal of Translational Autoimmunity, 2021
Background: Interleukin (IL)-17 and T helper 17 (TH17) cells, a distinct subset of CD4+ T cells which promotes the expression of IL-17, mediate host defensive mechanisms to various infections and are involved in the pathogenesis of autoimmune diseases ...
Shintaro Akiyama, Atsushi Sakuraba
doaj   +1 more source

Living with Psoriasis Vulgaris and Multi-Treatment Failure: A Patient and Dermatologist Perspective

Dermatology and Therapy, 2023
Psoriasis vulgaris is a systemic, chronic inflammatory disease affecting 2–3% of the population. Recent advances in the understanding of the pathophysiology of psoriatic disease have facilitated the development of novel therapeutic options with improved ...
Riley K. Spencer, Kareem G. Elhage, Joy Q. Jin, Mitchell S. Davis, Marwa Hakimi, Tina Bhutani, Howard Chang, Wilson Liao   +7 more
doaj   +1 more source

Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis

Frontiers in Immunology, 2023
The risk of infection and malignancy may be a concern for patients with psoriasis receiving interleukin (IL)-17 and IL-23 inhibitors, particularly with long-term treatments.
Shuwei Wu, Shuwei Wu, Yuanyuan Xu, Yuanyuan Xu, Lihua Yang, Lihua Yang, Linghong Guo, Linghong Guo, Linghong Guo, Xian Jiang, Xian Jiang   +10 more
doaj   +1 more source

Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

The Lancet Regional Health. Europe, 2022
Summary: Background: Biologics directed against the T-helper (Th)-17 pathway have been approved for several inflammatory diseases. Interleukin (IL)-17 is involved in anti-Candida host defense, and clinical trials suggested increased candidiasis ...
Linda Davidson, Juul M.P.A. van den Reek, Mariolina Bruno, Florence van Hunsel, Ron M.C. Herings, Vasiliki Matzaraki, Collins K. Boahen, Vinod Kumar, Hans M.M. Groenewoud, Frank L. van de Veerdonk, Mihai G. Netea, Elke M.G.J. de Jong, Bart Jan Kullberg   +12 more
doaj   +1 more source

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study

Trials, 2021
Background Psoriasis is a chronic immune-mediated inflammatory skin disease for which biologics are effective treatments. Dose reduction (DR) of the first generation biologics seems a promising way for more efficient use of expensive biologics.
Lara S. van der Schoot, Juul M. P. A. van den Reek, Lynda Grine, Lisa Schots, Wietske Kievit, Jo L. W. Lambert, Elke M. G. J. de Jong   +6 more
doaj   +1 more source

Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis

Frontiers in Immunology, 2022
BackgroundCoronavirus disease 2019 (COVID-19) have brought great disaster to mankind, and there is currently no globally recognized specific drug or treatment.
Meitong Liu, Huijuan Wang, Lu Liu, Saijin Cui, Xiangran Huo, Zhuoyun Xiao, Yaning Zhao, Bin Wang, Guoqiang Zhang, Guoqiang Zhang, Na Wang   +10 more
doaj   +1 more source

Secukinumab-induced Oral Lichen Planus: A Report of Case and Review of Literature

İstanbul Medical Journal, 2021
Recent years, we are witnessing a more frequent use of biological agent treatments. Secukinumab (SEC) has been used successfully in the management of psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Munise Daye, Selami Aykut Temiz, Selim Gümüş, Fahriye Kılınç   +3 more
doaj   +1 more source

Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis

Arthritis Research & Therapy, 2020
Objectives To systematically assess the efficacy and safety of IL-17 inhibitors in patients with active ankylosing spondylitis. Methods A systematic review of the literature was performed for randomized controlled trials (RCTs) concerning IL-17 ...
Yufeng Yin, Mingjun Wang, Mengru Liu, Erye Zhou, Tian Ren, Xin Chang, Michun He, Keqin Zeng, Yufan Guo, Jian Wu   +9 more
doaj   +1 more source

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis

Frontiers in Pharmacology, 2019
Psoriasis, an inflammatory skin disease, and psoriatic arthritis (PsA), an inflammatory arthritis, share clinical, genetic, and pathogenic factors and may be summed as one disease, the psoriatic disease.
Lazaros I. Sakkas, Efterpi Zafiriou, Dimitrios P. Bogdanos   +2 more
doaj   +1 more source

Unveiling the IL-17 axis: an immunometabolic bridge between psoriasis and metabolic syndrome

Journal of Dermatological Treatment
Aim of the review Psoriasis is increasingly recognized as a systemic inflammatory disease frequently associated with a cluster of cardiometabolic comorbidities, including obesity, type 2 diabetes, and cardiovascular disease.
Paolo Gisondi, Zeno Fratton, Ralph Vighi da Rosa, Vittoria Bellini, Andrea Carugno   +4 more
doaj   +1 more source